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i:10.1016/j.ijsu.2006.09.001Abstract Pancreatic cancer is an important cause of morbidity and mortality but there are
presently few if any prognostic markers available beyond tumour stage and grade. As tumours
are detected and treated at earlier stages these factors are less prognostically informative and
there is a growing need for development of novel diagnostic markers to guide pre- and post-
operative treatment. Additionally the outcome of surgery for pancreatic cancer remains
poor, largely due to late clinical presentation of most cases, and early detection, particularly
in high risk groups, such as those with chronic pancreatitis, Intraductal papillary mucinous
cystadenoma (IPMN) would enable earlier surgical intervention and improved survival. Use
of gene expression profiles represents an innovative approach to cancer classification and
prognostication and has been applied to an increasingly wide range of cancers. Recent studies
have identified prognostically informative gene signatures for pancreatic cancer, and there is
now an urgent need to develop methods for their measurement in routine clinical samples.
ª 2006 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.Introduction
Pancreatic cancer continues to have one of the highest
mortality rates of any malignancy. The vast majority of
patients are diagnosed at an advanced stage because
currently there are no tumour markers that allow reliable
screening for pancreatic cancer at a potentially curable
early stage. This is particularly important in pancreatic
cancer precursor conditions such as chronic pancreatitis,161 276 4250; fax: þ44 0161
.org.uk (K.S. Goonetilleke).
6 Published by Elsevier Ltd on beintraductal papillary mucinous cystadenoma (IPMN) and
those with a strong familial history of pancreatic cancer.
The genetic changes involved in the pathogenesis of
pancreatic cancer are not fully understood. However, the
role of a few known oncogenes (kras) and tumour suppres-
sor genes (p53, p16INK4A, SMAD4) is well established.1,2 In
addition to these alterations, cytogenetic and molecular
cytogenetic studies have revealed frequent chromosomal
structural aberrations including translocations, amplifica-
tions and deletions as a hallmark genomic feature of this
cancer. For example comparative genomic hybridisation
(CGH) analyses have identified frequent gains mapped to
3q, 5p, 7p, 8q, 11q, 12p, 17q, and 20q and losses to 3p,
4q, 6q, 8p, 9p, 10q, 12q. In some instances validated onco-
genes and tumour suppressor genes residing within thesehalf of Surgical Associates Ltd.
82 K.S. Goonetilleke, A.K. Siriwardenaloci have been identified, i.e. MYC(8q24), p16INK4A(9p21),
p53(17p13), SMAD4(18q21), and AKT2(19q13).3e5
Currently there is a strong emergence of data with
molecular profiling of pancreatic cancer. CGH, karyotype
analyses, and more recently DNA microarray based methods
are being used for gene expression profiles that provide
important information about the molecular characteristics
of pancreatic cancer. The differentially expressed genes
have potential for the development of new screening tests
to detect early pancreatic cancer and may serve as
important therapeutic applications such as development
of cell mediated immunotherapy.6e8
Molecular profiling of pancreatic adenocarcinoma
and chronic pancreatitis
Several studies based on the DNA microarray methods have
revealed a considerable number of differentially expressed
genes implicated in pancreatic cancer. Iacobuzio-Donahue
et al. identified more than 400 differentially expressed
genes in pancreatic cancer. These genes were linked to
multiple cellular processes such as cellecell and celle
matrix interactions, cytoskeletal remodelling, and Ca2þ
homeostasis.9 Similarly Missiaglia et al. described genetic
expression profiles obtained from 20 pancreatic cancer
cell lines using cDNA microarray containing 9932 human
gene elements. Numerous genes were identified as being
differentially expressed in pancreatic cancer some of which
have been previously implicated, i.e. S100P, S100A4, pros-
tate stem cell antigen, lipocalin 2, claudins 3 and 4, trefoil
factors 1 and 2 as well as several novel genes involved in
a variety of cellular functions, including control of tran-
scription, regulation of the cell cycle, proteolysis, cell
adhesion and signalling.10
A recent study by Logsdon et al.11 compared the differ-
entially expressed genes in pancreatic adenocarcinoma
with chronic pancreatitis and identified 158 highly ex-
pressed genes (>2 fold, p < 0.01) of which 124 were not
previously associated with pancreatic cancer. A key feature
of this study was the comparison of pancreatic cancer to
chronic pancreatitis in order to avoid the confounding com-
mon stromal genes expressed by both diseases to determine
cancer specific genes, i.e. 14-3-3s, S100P, S100A6, and b4
integrin. Binkley et al.12 performed a microarray analysis
of 6800 different genes expressed in pancreatic adenocarci-
noma (PC) and chronic pancreatitis (CP) to establish those
genes common to both pathologies and identified 107 genes
expressed within cells of the stromal compartment of both
PC and CP. These genes are likely important factors in the
epithelial-stromal signalling in pancreatic desmoplasia,
and may prove to be useful early indicator genes in progres-
sion from CP to PC.
Gene expression profiling in pancreatic juice of
patients with pancreatic cancer
Ishikawa et al.13 conducted an experimental trial for the di-
agnosis of pancreatic ductal carcinoma based on the gene
expression profiles of pancreatic ductal cells obtained
from pancreatic juice from patients with PC and normal
pancreas, undergoing ERCP. With the expression profilesof only five predictor genes, this method yielded an accu-
racy of 82% in differentiating PC and non-cancer. Thus,
microarray analysis of purified pancreatic ductal cells
obtained from pancreatic juice may provide a basis for
the development of a sensitive method for the detection
of pancreatic cancer in the future. The sensitivity of this
study was far superior to that of cytological examination
of pancreatic juice.14
A recent study by Yoshida et al.15 used real time PCR as
a tool for screening of genes specifically activated in the
pancreatic juice ductal cells from patients with pancreatic
cancer. They showed that genes such as SUMO1, AC133,
CEACAM7 were highly expressed in pancreatic juice derived
pancreatic ductal cells compared with normal pancreatic
juice. These results were consistent with microarray data,
thus suggesting the use of pancreatic juice from patients
with suspected/confirmed pancreatic cancer may serve as
a surrogate for tissue in the diagnosing of pancreatic cancer
in the future.
Apomucins expressed in pancreatic cancer
Mucin is a high molecular weight glycoprotein consisting of
core proteins (apomucins). Recently genes for apomucins
have been identified, cloned and characterised. At least
seven genes for apomucins are available at present.16e18
Mucinous cystadenomas which is considered premalig-
nant along with intraductal papillary mucinous neoplasm
(IPMN) of the pancreas characteristically contain high
amounts of mucin.19,20 A study by Terada et al.21 investi-
gated the expression of apomucins (MUC 1e7) in pancreatic
neoplasms. Their results suggest that MUC3 and MUC 5/6
apomucins newly emerge during the neoplastic transforma-
tion of pancreatic mucinous cystadenoma and IPMN during
pancreatic ductal carcinogenesis. Apomucin 2 remains neg-
ative throughout the transformation.
Discussion
The current challenges in pancreatic cancer are detecting
the disease early so that curative resection can be un-
dertaken and new approaches developed to treat the
disease. The characterization of the gene expression
patterns in pancreatic cancer tissues and cell lines by
cDNA microarray or RT-PCR analysis provides validation of
a number of genes with promise for development into novel
therapeutic or diagnostic targets, along with clues to
additional cellular pathways that may play a role in the
biology of this deadly cancer.
Numerous genes have been implicated in therapeutic
strategies for pancreatic cancer. These include genes
characteristically induced by interferon or retinoic acid
stimulation. Both interferons and retinoids have been
shown to play a role in the cell growth and differentiation
of pancreatic cancer cells.22,23 Clinical trials are currently
ongoing to better evaluate the effects of interferon and
retinoic acid therapy on patients with advanced pancreatic
carcinoma.24 The differential expression of these genes
among pancreatic cancers suggests that their expression
may prove useful in predicting which patients might benefit
from interferon or retinoic acid treatment.
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p8, LIMK2 correlate well with the number of metastatic
lymph nodes involved.25,26 Thus, further exploration of these
genes would shed more light on identifying patients with
lymph node metastasis prior to undergoing resection.
It is expected that a number of genes will be identified
for which the expression in either pancreatic juice or
exfoliated ductal cells will reflect expression in pancreatic
tissue and that these genes will therefore enable non-
invasive diagnosis and monitoring. This should be achieved
by developing a simple, rapid, inexpensive, sensitive and
robust means of preparing informative representative cDNA
from patient samples, specifically from pancreatic juice,
exfoliated pancreatic ductal cells for an ERCP sensitive and
specific test for the detection of pancreatic cancer.
In conclusion, it is clearly evident that the gene
expression of pancreatic cancer holds a unique place for
the potential development of early diagnostic, screening
tools, and therapies for pancreatic cancer in the future.
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